Psychedelic Science Newsletter
Issue #13December 1, 20257 studies

Mystical experiences predict PTSD recovery after ibogaine, while psychedelic gene expression maps to human brain evolution

Two fascinating studies this week reveal how psychedelics work at both the mystical and molecular level—from predicting who recovers from PTSD to uncovering ancient genetic programs that shape consciousness.

🌟 Mystical Experiences Predict PTSD Recovery After Ibogaine

  • 30 male veterans with traumatic brain injury received magnesium-ibogaine therapy and were assessed using the Mystical Experiences Questionnaire

  • Veterans reporting more intense mystical experiences showed dramatically larger reductions in PTSD symptoms both immediately after treatment (5.89-point greater improvement) and one month later (4.45-point greater improvement)

  • The mystical experience intensity also correlated with specific brain changes—greater reductions in peak alpha frequency, an EEG measure linked to ibogaine's therapeutic effects

Why it matters: This suggests that the subjective mystical experience during ibogaine treatment isn't just a side effect—it may be a key predictor of therapeutic success for PTSD recovery.

🥉 Top 5% journal 🔗 Journal of Affective Disorders 🗓️ Nov 20

Key Findings

🧬 Psychedelic Genes Linked to Human Brain Evolution

  • Researchers mapped genes that respond to psychedelics across animal studies and cell cultures, then cross-referenced them with the Allen Human Brain Atlas to identify high-confidence psychedelic-responsive genes in humans

  • These genes were enriched in cortical pyramidal neurons (layers 5 and 6) and associated with neuron projection and spine morphology

  • Strikingly, psychedelic-responsive genes were overrepresented among human accelerated genes—genetic sequences that evolved rapidly during human evolution

💡 Psychedelics may tap into ancient genetic programs that helped shape human consciousness during evolution.
🔗 Research square 🗓️ Nov 19

🎯 Psilocybin Changes How We See Visual Context

  • Researchers used ultra-high field fMRI and the Ebbinghaus illusion (where circles appear different sizes based on surrounding context) to test psilocybin's effects on visual perception

  • Psilocybin altered both how people perceived contextual illusions and how their brains processed contextual visual information

  • A computational model successfully captured and linked these perceptual and neural changes

💡 Altering contextual computations may be a fundamental mechanism underlying how psychedelics change perception and consciousness.
🥈 Top 2% journal 🔗 Nature Communications 🗓️ Nov 21

🔬 Psilocybin Matches Antidepressant for Emotional Processing

  • 59 patients with moderate-to-severe depression were randomly assigned to receive either psilocybin (25mg twice) or escitalopram (daily for 6 weeks), both with psychological support

  • Both treatments equally reduced negative bias in facial emotion recognition compared to baseline

  • For escitalopram patients specifically, reduced misclassification of positive faces as negative was associated with lower depression scores at 1-month follow-up

💡 Psilocybin and traditional antidepressants may share some cognitive mechanisms despite vastly different dosing regimens.
🥉 Top 5% journal 🔗 Translational Psychiatry 🗓️ Nov 19

🧪 Ketamine's Anti-Inflammatory Effects May Drive Antidepressant Action

  • Mice given lipopolysaccharide (LPS) to induce depression-like behavior were treated with ketamine (10-20 mg/kg)

  • Ketamine reduced despair and anhedonia while decreasing brain inflammation—specifically reducing neutrophils, dampening microglial activation, and blocking monocyte infiltration into the brain

  • In the spleen, ketamine increased anti-inflammatory immune cells and polarized macrophages toward an M2 phenotype

💡 Ketamine's rapid antidepressant effects may work partly through immune system modulation, not just brain receptor changes.
🥈 Top 2% journal 🔗 Molecular Psychiatry 🗓️ Nov 18

💊 Computer Models Test Psychedelics for Consciousness Disorders

  • Researchers created individualized brain models for patients with disorders of consciousness and simulated LSD and psilocybin administration

  • The simulated psychedelics shifted brain activity closer to criticality (the sweet spot between order and chaos) with greater effects in minimally conscious patients than unresponsive ones

  • Treatment response correlated with structural brain connectivity in unresponsive patients but with functional connectivity in minimally conscious patients

💡 Virtual clinical trials could help identify which consciousness disorder patients might benefit most from psychedelic therapies.
🥈 Top 2% journal 🔗 Advanced Science 🗓️ Nov 20

⚠️ Psychedelics During Pregnancy Disrupt Mouse Brain Development

  • Pregnant mice given LSD (0.3 mg/kg) showed the drug crossing the placenta and appearing in embryonic brain fluid within minutes

  • A single exposure at embryonic day 12.5 altered brain layer organization, while repeated dosing increased male-biased shifts in neuron types and microglia

  • Adult offspring showed reduced prepulse inhibition (a measure of sensory filtering) and increased repetitive behaviors, particularly in males

💡 Prenatal psychedelic exposure may have lasting effects on brain development and behavior, highlighting safety concerns during pregnancy.

Implications

These studies reveal psychedelics work through multiple pathways—from mystical experiences that predict therapeutic outcomes to ancient genetic programs tied to human evolution. The convergence of anti-inflammatory effects, visual processing changes, and developmental impacts suggests these compounds tap into fundamental brain mechanisms that evolved over millions of years.

Studies in this issue

Primary sources used for this newsletter.

  1. Magnesium-Ibogaine’s mystical experiences linked to better PTSD symptoms in veterans
    main storyJournal of affective disorders2025-11-20PMID 41265656
  2. Psychedelic use during pregnancy may disturb brain growth and behavior in mouse offspring
    key findingbioRxiv : the preprint server for biology2025-11-19PMID 41256514
  3. Negative emotional bias in depression after treatment with psilocybin or escitalopram
    key findingTranslational psychiatry2025-11-19PMID 41257994
  4. Using Psychedelics to Help Patients with Severe Consciousness Disorders
    key findingAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025-11-20PMID 41261994
  5. Psilocybin changes how the brain processes visual context
    key findingNature communications2025-11-21PMID 41271688
Mystical experiences predict PTSD recovery after ibogaine, while psychedelic gene expression maps to human brain evolution | Psychedelic Science Issue #13 | OpenScience.ink